BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25006120)

  • 1. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
    Döhner H; Lübbert M; Fiedler W; Fouillard L; Haaland A; Brandwein JM; Lepretre S; Reman O; Turlure P; Ottmann OG; Müller-Tidow C; Krämer A; Raffoux E; Döhner K; Schlenk RF; Voss F; Taube T; Fritsch H; Maertens J
    Blood; 2014 Aug; 124(9):1426-33. PubMed ID: 25006120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
    Kobayashi Y; Yamauchi T; Kiyoi H; Sakura T; Hata T; Ando K; Watabe A; Harada A; Taube T; Miyazaki Y; Naoe T
    Cancer Sci; 2015 Nov; 106(11):1590-5. PubMed ID: 26471242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
    Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
    J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
    Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
    Schliemann C; Gerss J; Wiebe S; Mikesch JH; Knoblauch N; Sauer T; Angenendt L; Kewitz T; Urban M; Butterfass-Bahloul T; Edemir S; Vehring K; Müller-Tidow C; Berdel WE; Krug U
    PLoS One; 2016; 11(10):e0164499. PubMed ID: 27716819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
    Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
    P Solans B; Fleury A; Freiwald M; Fritsch H; Haug K; Trocóniz IF
    Clin Pharmacokinet; 2018 Mar; 57(3):379-392. PubMed ID: 28631179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
    Döhner H; Symeonidis A; Deeren D; Demeter J; Sanz MA; Anagnostopoulos A; Esteve J; Fiedler W; Porkka K; Kim HJ; Lee JH; Usuki K; D'Ardia S; Won Jung C; Salamero O; Horst HA; Recher C; Rousselot P; Sandhu I; Theunissen K; Thol F; Döhner K; Teleanu V; DeAngelo DJ; Naoe T; Sekeres MA; Belsack V; Ge M; Taube T; Ottmann OG
    Hemasphere; 2021 Aug; 5(8):e617. PubMed ID: 34350385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
    Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
    Kantarjian HM; Martinelli G; Jabbour EJ; Quintás-Cardama A; Ando K; Bay JO; Wei A; Gröpper S; Papayannidis C; Owen K; Pike L; Schmitt N; Stockman PK; Giagounidis A;
    Cancer; 2013 Jul; 119(14):2611-9. PubMed ID: 23605952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    Cortes J; Podoltsev N; Kantarjian H; Borthakur G; Zeidan AM; Stahl M; Taube T; Fagan N; Rajeswari S; Uy GL
    Int J Hematol; 2021 Jan; 113(1):92-99. PubMed ID: 32951163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Dennis M; Burnett A; Hills R; Thomas I; Ariti C; Severinsen MT; Hemmaway C; Greaves P; Clark RE; Copland M; Russell N;
    Br J Haematol; 2021 Jul; 194(2):298-308. PubMed ID: 33961292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
    Burnett AK; Hills RK; Hunter A; Milligan D; Kell J; Wheatley K; Yin J; McMullin MF; Cahalin P; Craig J; Bowen D; Russell N
    Leukemia; 2011 Jul; 25(7):1122-7. PubMed ID: 21475252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
    Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
    Robles C; Kim KM; Oken MM; Bennett JM; Letendre L; Wiernik PH; O'Connell MJ; Cassileth PA
    Leukemia; 2000 Aug; 14(8):1349-53. PubMed ID: 10942228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Berdel AF; Koch R; Gerss J; Hentrich M; Peceny R; Bartscht T; Steffen B; Bischoff M; Spiekermann K; Angenendt L; Mikesch JH; Kewitz T; Butterfass-Bahloul T; Serve H; Lenz G; Berdel WE; Krug U; Schliemann C
    Ann Hematol; 2023 Jan; 102(1):63-72. PubMed ID: 36399194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
    Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
    Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
    Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.